Table 4.

Latent class logit model with five classes

Attribute	Class 1	Class 2	Class 3	Class 4	Class 5
Latent class logit mdoel
ASC	81.735	124.144	48.588	48.221	46.778
Vaccine origin
Canada	(Reference)
European Union	−0.105	−10.233***	−0.434**	−1.007***	−0.660***
USA	−0.093	−6.369***	−0.738***	−0.995***	−0.678***
Japan	−0.053	−13.377***	−0.510***	−1.697***	−0.700***
Russia	−0.048	−16.034***	−0.731***	−2.697***	−0.883***
China	0.090	−18.225***	−1.017***	−3.478***	−0.810***
Vaccine effectiveness (%)
95	(Reference)
85	0.030	−7.679***	−0.370**	−0.109	−0.721***
60	−0.204	−9.292***	−1.143***	−0.455***	−1.996***
30	−0.214	−23.843***	−3.126***	−1.121***	−4.191***
Side effects of the vaccine
Redness and mild itching	(Reference)
Mild fevers	0.004	0.657**	−0.200*	−0.096	0.055
Hospitalization	−0.204*	−40.397***	−4.315***	−0.417***	−0.671***
Duration of vaccine protection (months)
24	(Reference)
9	0.047	−0.314**	−0.614***	−0.168	−0.546***
3	0.016	−3.558***	−1.454***	−0.456***	−1.211***
Priority population to receive the vaccine
65 years and over	(Reference)
Healthcare workers	−0.004	−5.035***	0.085	0.005	−0.008
No priority population	−0.133	−4.047***	−0.119*	0.057	−0.045
Waiting time to get vaccinated (months)
2	(Reference)
4	−0.095	−10.415***	0.274*	0.045	−0.069
8	−0.257**	−8.200***	−0.115*	−0.182	−0.132
Recommender of the vaccine
World Health Organization and Quebec Public Health Department	(Reference)
Quebec Public Health Department	−0.087	−4.785***	−0.709***	−0.599***	−0.160*
World Health Organization	−0.305***	−2.505***	−0.898***	−0.581***	−0.168*
Class share	0.117	0.097	0.308	0.195	0.283
Observations	1599
LLF	−6020.47
AIC	12,238.95

AIC Akaike Information Criterion, ASC alternative specific constant, LLF likelihood function, *$p<0.1;$ **$p<0.05;$ ***$p<0.01$